Regenxbio (RGNX) Misses Q4 EPS by 28c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
February 26, 2020 4:05 PM ESTROCKVILLE, Md., Feb. 26, 2020 /PRNewswire/ --
Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020 RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy expected to advance in 2020 using subretinal and suprachoroidal delivery approaches Additional interim data from RGX-121 Phase I/II trial for MPS II expected in 2020 Plans to expand rare disease pipeline into neuromuscular disorders in 2H 2020 $400 million in cash, cash equivalents and marketable securities as of December 31, 2019 Conference call Wednesday, February 26th at... More